RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Revenue

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndRevenue (Million USD)YoY (%)
Dec 31, 202414,202+8.27%
Dec 31, 202313,117+7.76%
Dec 31, 202212,173-24.26%
Dec 31, 202116,072+89.14%
Dec 31, 20208,497+8.06%
Dec 31, 20197,863+17.18%
Dec 31, 20186,711+14.28%
Dec 31, 20175,872+20.82%
Dec 31, 20164,860+18.44%
Dec 31, 20154,104+45.55%
Dec 31, 20142,820+33.96%
Dec 31, 20132,105+52.69%
Dec 31, 20121,378+209.20%
Dec 31, 2011446-2.89%
Dec 31, 2010459

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)